目前担任首都医科大学附属北京天坛医院北京市神经外科研究所流行病学研究室副主任、首都医科大学临床流行病学与临床试验学系办公室主任、首都医科大学附属北京天坛医院-国家神经系统疾病临床医学研究中心统计组长，团队将依托三个平台开展研究工作：

        北京市神经外科研究所流行病学研究室创建于1980年，是国内首家从事神经系统疾病流行病学和人群防治研究的专业机构。自成立以来，流行病学研究室多次组织完成国内大规模流行病学研究课题，在脑血管病、癫痫、老年痴呆等社区人群防治措施研究方面积累了丰富的经验。连续承担国家科技部“七五”、“八五”、“九五”、“十五”、“十一五”、“十二五”重大疾病攻关课题以及国际合作研究课题多项。荣获国家科技进步奖2项，中华医学科技二等奖1项，北京市科技进步奖、卫生部科技进步奖等十余项。

       国家神经系统疾病临床医学研究中心是目前国内规模最大的神经系统疾病领域临床医学研究平台，拥有临床数据与生物样本库、研究方法学部门、多组学实验中心、脂代谢与动脉粥样硬化中心等支撑平台，配置了 2560 核计算机超算平台等硬件设施及 SAS、PASS 等正版统计分析软件。统计学部负责临床研究设计、统计分析、数据管理，并开展健康医疗大数据分析方法应用研究及培训，为开展高质量的临床研究和人群防治研究提供流行病学和统计学方法技术支撑，策划并参与了“CNSR Ⅰ-Ⅲ”、“CHANCE Ⅰ-Ⅲ”、“开滦研究”等多项大型研究。

       首都医科大学临床流行病学与临床试验学系依托于流行病与卫生统计学二级学科，同时开展学历教育与非学历教育，由首都医科大学附属北京天坛医院、宣武医院、附属北京朝阳医院、附属北京安贞医院、公共卫生学院等 32 家临床医学院、附属医院、教学医院及学院组成。学系系务委员会现有委员 76 名，其中教授 20 名，副教授 11 名，由王拥军教授任委员会主任，陈瑞、张兰、刘丽宏、王伊龙、林阳等教授任委员会副主任。学系下设临床流行病学、临床试验学及临床药学 3 个学组，分别由刘静教授、王伊龙教授及刘丽宏教授担任学组负责人，充分整合了 3 个学组的专家资源和专业优势，形成了国内综合实力领先、具有国际竞争能力的学术人才梯队，为培养高素质、复合型人才莫定了坚实基础。

       研究团队现有成员 27 人，多人具备交叉学科教育背景，包括流行病学、统计学、神经病学、内科学、卫生事业管理学、生物信息学、临床药学、护理学等，全职工作人员均为流行病与卫生统计学专业博士。团队近五年承担及参与国家级和省部级课题 10 余项，在 BMJ、NEJM、Annals of Internal Medicine、JAMA Neurology、MED、Neurology、Annals of Neurology、JAMA Network Open、BMC Medicine、Stroke 及 Hypertension 等高质量杂志发表 SCI 文章 200 余篇。

主持的在研项目：

1. 十四五国家重点研发计划，600万

2. 国家自然科学基金（面上项目），49万

3. 首都卫生发展科研专项项目（自主创新），126.8万

4. 北京市自然科学基金-海淀原始创新联合基金，29.3万

5. “长江学者奖励计划”青年学者，30万

6. 北京市高层次公共卫生技术人才建设项目-学科骨干，42万

7. 首都医科大学优秀青年人才项目-A类，150万

8. 首都医科大学附属北京天坛医院“青年科学家计划”，60万

主编或副主编的著作/译著：

1. 《天坛临床试验手册》，副主编，科学出版社，202305

重要奖项：

1. Stanford University、Elsevier, 2024 World's Top 2% Scientists

2. 北京市科学技术协会，首都前沿学术成果，202408

3. ISC 2023 Paul Dudley White International Scholar Award

4. 2022年中国脑血管病临床研究进展十大进展奖 

近五年重要学术论文：

[1] SU D, CUI Y, HE C, et al. Projections for Prevalence of Parkinson's Disease and Its Driving Factors in 195 Countries and Territories to 2050: Modelling Study of Global Burden of Disease Study 2021 [j]. BMJ (Clinical Research ed), 2025;388:e080952. doi: 10.1136/bmj-2024-080952

[2]FU Y, WANG A, TANG R, et al. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial [J]. JAMA Neurol, 2024, 81(4): 319-26.

[3]WANG A, JIA B, ZHANG X, et al. Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial [J]. JAMA Neurol, 2023, 80(8): 851-9.

[4]WANG A, XIE X, TIAN X, et al. Ticagrelor-Aspirin Versus Clopidogrel-Aspirin Among CYP2C19 Loss-of-Function Carriers With Minor Stroke or Transient Ischemic Attack in Relation to Renal Function: A Post Hoc Analysis of the CHANCE-2 Trial [J]. Annals of Internal Medicine, 2022, 175(11): 1534-42.

[5]ZHU J, CUI Y, ZHANG J, et al. Temporal trends in the prevalence of Parkinson's disease from 1980 to 2023: a systematic review and meta-analysis [J]. Lancet Healthy Longev, 2024, 5(7): e464-e79.

[6]WANG A, TIAN X, JIANG D, et al. Rehabilitation with brain-computer interface and upper limb motor function in ischemic stroke: A randomized controlled trial [J]. Med, 2024, 5(6): 559-69 e4.

[7]XIA X, TIAN X, XU Q, et al. Global trends and regional differences in mortality of cardiovascular disease and its impact on longevity, 1980-2021: Age-period-cohort analyses and life expectancy decomposition based on the Global Burden of Disease study 2021 [J]. Ageing Res Rev, 2024, 103: 102597.

[8]ZHANG Q, WANG A, XU Q, et al. Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke: A Randomized Clinical Trial [J]. JAMA Netw Open, 2023, 6(8): e2328828.

[9]WANG A, TIAN X, XIE X, et al. Effects of remnant cholesterol on the efficacy of genotype-guided dual antiplatelet in CYP2C19 loss-of -function carriers with minor stroke or transient ischaemic attack: a post-hoc analysis of the CHANCE-2 trial [J]. EClinicalMedicine, 2024, 67: 102357.

[10]WANG A, TIAN X, XIE X, et al. Differential effect of ticagrelor versus clopidogrel by homocysteine levels on risk of recurrent stroke: a post hoc analysis of the CHANCE-2 trial [J]. CMAJ, 2024, 196(5): E149-E56.

[11]LI Y, WU S, GAO J, et al. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD [J]. Am J Kidney Dis, 2023, 83(4): 477-88.

[12]ZHANG J, WANG A, TIAN X, et al. Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack [J]. CMAJ, 2023, 195(26): E897-E904.

[13]XING A, TIAN X, WANG Y, et al. 'Life's Essential 8' cardiovascular health with premature cardiovascular disease and all-cause mortality in young adults: the Kailuan prospective cohort study [J]. Eur J Prev Cardiol, 2023, 30(7): 593-600.

[14]WANG A, MENG X, TIAN X, et al. Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack [J]. Ann Neurol, 2022, 91(3): 380-8.

[15]WU S, LI Y, ZHANG Y, et al. Sex and Age Differences in the Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Heart Failure: A Prospective Cohort Study [J]. Circ Heart Fail, 2024, 17(2): e010841.

[16]WU S, WU Z, YU D, et al. Life's Essential 8 and Risk of Stroke: A Prospective Community-Based Study [J]. Stroke, 2023, 54(9): 2369-79.

[17]TIAN X, CHEN S, XU Q, et al. Cumulative Serum Uric Acid Exposure and Its Time Course With the Risk of Incident Stroke [J]. Stroke, 2023, 54(8): 2077-86.

[18]WANG A, MENG X, TIAN X, et al. Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack [J]. Stroke, 2022, 53(9): 2799-808.

[19]LI H, QIAN F, ZUO Y, et al. U-Shaped Relationship of High-Density Lipoprotein Cholesterol and Incidence of Total, Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study [J]. Stroke, 2022, 53(5): 1624-32.

[20]XU J, WANG A, MENG X, et al. Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial [J]. Stroke, 2021, 52(3): 772-80.

[21]MENG X, WANG A, TIAN X, et al. One-Year Outcomes of Early Therapy With Ticagrelor vs Clopidogrel in CYP2C19 Loss-of-Function Carriers With Stroke or TIA Trial [J]. Neurology, 2024, 102(3): e207809.

[22]YANG M, WANG A, LI J, et al. Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis [J]. Neurology, 2020, 94(2): e181-e9.

[23]TIAN X, CHEN S, ZUO Y, et al. Association of lipid, inflammatory, and metabolic biomarkers with age at onset for incident cardiovascular disease [J]. BMC Med, 2022, 20(1): 383.

[24]WANG A, TIAN X, ZUO Y, et al. Control of Blood Pressure and Risk of Cardiovascular Disease and Mortality in Elderly Chinese: A Real-World Prospective Cohort Study [J]. Hypertension (Dallas, Tex : 1979), 2022, 79(8): 1866-75.

[25]TIAN X, ZUO Y, CHEN S, et al. Hypertension, Arterial Stiffness, and Diabetes: a Prospective Cohort Study [J]. Hypertension, 2022, 79(7): 1487-96.

[26]TIAN X, CHEN S, XIA X, et al. Causal Association of Arterial Stiffness With the Risk of Chronic Kidney Disease [J]. JACC Asia, 2024, 4(6): 444-53.

[27]ZUO Y, CHEN S, TIAN X, et al. Association of Vascular Aging With Cardiovascular Disease in Middle-Aged Chinese People: A Prospective Cohort Study [J]. JACC Asia, 2023, 3(6): 895-904.

[28]WANG A, LI H, YUAN J, et al. Visit-to-Visit Variability of Lipids Measurements and the Risk of Stroke and Stroke Types: A Prospective Cohort Study [J]. J Stroke, 2020, 22(1): 119-29.